Adjuvant trastuzumab: does time really matter? - Wikidata - awgldk - TriplyDB

Adjuvant trastuzumab: does time really matter?

Adjuvant trastuzumab: does time really matter?

http://www.wikidata.org/entity/Q36871644

about

Adjuvant trastuzumab: does time really matter?

http://www.wikidata.org/entity/Q36871644

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Adjuvant trastuzumab: does time really matter?

@en

type

label

Adjuvant trastuzumab: does time really matter?

@en

prefLabel

Adjuvant trastuzumab: does time really matter?

@en

P1433

Q36871644-F82798D7-F70B-4109-910D-CCA9F6AB6F57

P1476

Q36871644-73C2EEAD-FBE9-44A3-9A2A-11F45E44021C

P2093

Q36871644-115C08FA-CFC4-40C4-907A-FA6E38084EA5

P2860

Q36871644-07270CB4-3BAF-4AEC-895C-951613A62F51

Q36871644-0F3426B8-40ED-4B9A-B36C-86B62004A354

Q36871644-180298DD-FEE5-469D-99F8-CFAEEE12A520

Q36871644-44BC147A-23B0-470F-AD17-814BB69D96A8

Q36871644-5426004A-61EF-412D-BFF8-A4AC91B09289

Q36871644-7A7EEDF7-0418-4A06-8986-3B9E60F09483

Q36871644-97A97B00-27EF-40E2-AE24-505F20F70A09

Q36871644-AC90F235-08F4-484A-87B9-608B58DC5D1D

Q36871644-B4EFAB18-30B1-4273-AF7C-E35C7F9D2D20

Q36871644-C853895A-F41E-4ED6-BCE2-EAF32B61269E

P304

Q36871644-68FB9799-E2B9-420B-97A5-C2E64EA5835F

P31

Q36871644-94F4DC24-9E3A-44AC-9F59-0D54BE3683B1

P356

Q36871644-E9B2D3B5-A9CE-4B22-B29C-0BDCF046A5BF

P433

Q36871644-68C2F4AD-CDDC-4B95-8F98-8C10959A39E3

P478

Q36871644-67D96EAA-7A6C-4293-95F0-92E4653D36D8

P577

Q36871644-9CD31909-13B8-487D-95FF-723C52FD062E

P5875

Q36871644-B822F9A9-9845-4206-A75E-6B9CA1FB40EF

P698

Q36871644-273F1641-4AD4-4D9A-9FD7-B221FA062801

P932

Q36871644-13597D56-B4AA-4A9F-9144-CE33CD67503D

P356

THEONCOLOGIST.2013-0094

P1433

P1476

Adjuvant trastuzumab: does time really matter?

@en

P2093

Sandra M Swain

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

Adjuvant trastuzumab in HER2-positive breast cancer.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

P304

490-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0094

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236459689

http://www.w3.org/2001/XMLSchema#string

P698

23624497

http://www.w3.org/2001/XMLSchema#string

P932

3662838

http://www.w3.org/2001/XMLSchema#string